MedPath

Warfarin

Generic Name
Warfarin
Brand Names
Coumadin, Jantoven
Drug Type
Small Molecule
Chemical Formula
C19H16O4
CAS Number
81-81-2
Unique Ingredient Identifier
5Q7ZVV76EI
Background

Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.

Indication

Indicated for:

1) Prophylaxis and treatment of venous thromboembolism and related pulmonary embolism.

2) Prophylaxis and treatment of thromboembolism associated with atrial fibrillation.

3) Prophylaxis and treatment of thromboembolism associated with cardiac valve replacement.

4) Use as adjunct therapy to reduce mortality, recurrent myocardial infarction, and thromboembolic events post myocardial infarction.

Off-label uses include:

1) Secondary prevention of stroke and transient ischemic attacks in patients with rheumatic mitral valve disease but without atrial fibrillation.

Associated Conditions
Myocardial Infarction, Pulmonary Embolism, Stroke, Systemic Embolism, Thromboembolism, Transient Ischemic Attack, Venous Thrombosis (Disorder)
Associated Therapies
-

Treatment of Upper Extremity Deep-Vein Thrombosis

Phase 4
Completed
Conditions
Deep-Vein Thrombosis
Interventions
First Posted Date
2005-10-28
Last Posted Date
2013-02-21
Lead Sponsor
University of Oklahoma
Target Recruit Count
67
Registration Number
NCT00245856
Locations
🇺🇸

Department of Veterans Affairs Medical Center, Oklahoma City, Oklahoma, United States

🇺🇸

University of Oklahoma Health Science Center, Oklahoma City, Oklahoma, United States

Odiparcil For The Prevention Of Venous Thromboembolism

Phase 2
Completed
Conditions
Deep Vein Thrombosis
Fibrillation, Atrial
Venous Thromboembolism
Pulmonary Embolism
First Posted Date
2005-10-27
Last Posted Date
2017-05-02
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
961
Registration Number
NCT00244725
Locations
🇬🇧

GSK Investigational Site, Wigan, United Kingdom

Aortic Arch Related Cerebral Hazard Trial (ARCH)

Phase 3
Completed
Conditions
Brain Infarction
Transient Ischemic Attack
Embolism
Interventions
Drug: Clopidogrel-aspirin
Drug: Warfarin
First Posted Date
2005-10-10
Last Posted Date
2012-07-10
Lead Sponsor
Assistance Publique - Hôpitaux de Paris
Target Recruit Count
350
Registration Number
NCT00235248
Locations
🇦🇺

National Stroke Research Institute-Austin Health, Heidelberg Heights, Australia

🇫🇷

Bichat Hospital Head of Neurology Department, Paris, France

The Catheter Study: Central Venous Catheter Survival in Cancer Patients Using Low Molecular Weight Heparin (Dalteparin) for the Treatment of Deep Vein Thrombosis

Phase 2
Completed
Conditions
Embolism and Thrombosis
First Posted Date
2005-09-22
Last Posted Date
2017-08-28
Lead Sponsor
Lawson Health Research Institute
Target Recruit Count
70
Registration Number
NCT00216866
Locations
🇨🇦

London Health Sciences Centre, London, Ontario, Canada

🇨🇦

Queen Elizabeth II Health Care Centre, Halifax, Nova Scotia, Canada

🇨🇦

St. Joseph's Healthcare, Hamilton, Ontario, Canada

and more 3 locations

Anticoagulation in Liver Fibrosis in Patients With Hepatitis C Virus Infection

Phase 2
Completed
Conditions
Liver Fibrosis
Interventions
First Posted Date
2005-09-16
Last Posted Date
2020-12-01
Lead Sponsor
Imperial College London
Target Recruit Count
14
Registration Number
NCT00180674
Locations
🇬🇧

St Mary's Hospital NHS Trust, London, United Kingdom

Determinants of Warfarin Metabolism

Not Applicable
Conditions
Healthy
Interventions
First Posted Date
2005-09-13
Last Posted Date
2018-06-12
Lead Sponsor
Hadassah Medical Organization
Target Recruit Count
600
Registration Number
NCT00162474
Locations
🇮🇱

Hadassah Medical Organization, Jerusalem, Israel

Genetic Determinants of Warfarin Anticoagulation Effect

Not Applicable
Conditions
Atrial Fibrillation
Venous Thrombosis
Pulmonary Embolism
Interventions
First Posted Date
2005-09-13
Last Posted Date
2018-06-12
Lead Sponsor
Hadassah Medical Organization
Target Recruit Count
500
Registration Number
NCT00162435
Locations
🇮🇱

Hadassah Medical Organization, Jerusalem, Israel

Access II - Trial of Warfarin to Prevent Malfunction of Haemodialysis Catheters

Phase 3
Completed
Conditions
Thrombosis
End Stage Renal Disease
Bleeding
Interventions
Drug: placebo
Drug: warfarin
First Posted Date
2005-09-12
Last Posted Date
2008-06-17
Lead Sponsor
Hamilton Health Sciences Corporation
Target Recruit Count
170
Registration Number
NCT00157651
Locations
🇨🇦

St. Joseph's Healthcare, Hamilton, Ontario, Canada

WATCHMAN Left Atrial Appendage System for Embolic PROTECTion in Patients With Atrial Fibrillation

Phase 2
Completed
Conditions
Atrial Fibrillation
Stroke
Interventions
Device: WATCHMAN Left Atrial Appendage Closure Technology
Drug: Warfarin
First Posted Date
2005-08-12
Last Posted Date
2015-05-15
Lead Sponsor
Boston Scientific Corporation
Target Recruit Count
800
Registration Number
NCT00129545
Locations
🇺🇸

Advanced Cardiac Specialists, Gilbert, Arizona, United States

🇺🇸

Mercy Medical Center West, Knoxville, Tennessee, United States

🇺🇸

St. John's Hospital / Pacific Heart, Santa Monica, California, United States

and more 59 locations

Warfarin and Antiplatelet Vascular Evaluation

Phase 3
Conditions
Peripheral Vascular Diseases
Cardiovascular Diseases
First Posted Date
2005-08-01
Last Posted Date
2009-09-29
Lead Sponsor
Anand, Sonia, M.D.
Target Recruit Count
2400
Registration Number
NCT00125671
Locations
🇨🇦

Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada

© Copyright 2025. All Rights Reserved by MedPath